Animal Alternative Technologies Competitors

No.1 Beauty Group Worldwide. No.1 most innovative company in Europe (Fortune's ranking). We are 90K employees across 150 countries on five continents, united by our shared purpose: creating the beauty that moves the world. Our 37 international brands are divided into four unique Divisions: Luxe, Consumer Products, Dermatological Beauty, and Professional Products. This diverse portfolio includes brands like Kiehl’s, Lancôme, Giorgio Armani Beauty, Yves Saint Laurent Beauté, Ralph Lauren, Aesop, Maybelline New York, Essie, Kérastase, IT Cosmetics, Prada Beauty, Biotherm, Shu Uemura, Viktor&Rolf, Maison Margiela, Urban Decay, Redken, Vichy, La Roche-Posay, Diesel, Garnier, L’Oréal Paris, and more. For more than a century, L’Oréal has devoted itself solely to one business: beauty. We want to bring beauty to all people. Our goal is to win over another one billion consumers around the world by innovating and creating cosmetic and skincare products that meet the infinite diversity of their beauty needs and desires. That’s about us… now what about you? You are driven and up for a challenge! You’re passionate about putting your best foot forward, but you’re not afraid to fail either. You love to learn, grow and make an impact on the world. You can be an intern, or at a senior level position, we’re always looking for new people to join our teams. If you are ready to take charge of your career and join us, you’re one click away: https://careers.loreal.com/en_US/content Interested about our quest to the next billion consumers, follow us here to get the insider scoop on our business, culture, and tips on how to join us to shape the future of beauty. Freedom to go beyond, that’s the beauty of L’Oréal.

Aspect Biosystems is a biotechnology company pioneering the development of a novel category of cellular medicines designed to replace or restore biological function and deliver curative therapies for some of the most elusive diseases. Aspect is developing these bioengineered cellular medicines by applying its full-stack tissue therapeutic platform, which integrates proprietary AI-powered bioprinting technology, therapeutic cells, hypoimmune cell engineering, and advanced biomaterials. Aspect is advancing its therapeutic pipeline across multiple endocrine and metabolic diseases, including diabetes and rare endocrine disorders.